Online Programs
(For Health Professionals)
Health Education Online Programs:
3) Or, scroll through the educational programs below!
ACS-WRAP: Focus on Oral Antiplatelet Therapy for Medical Management of ACS
Charles V. Pollack, Jr., MD, FACEP, Professor and Chairman, Emergency Medicine at Pennsylvania Hospital, examines the risk- and setting-directed deployment of oral antiplatelet agents, from symptom onset to hospital discharge for the ACS patient.
Cardioprotection in Type 2 Diabetes
Herzel Gerstein, MD, of McMaster University, leads a national panel of experts in reviewing the role of early insulin therapy for optimizing cardiovascular risk reduction across the dysglycemic continuum for type 2 diabetes. A close look at what the landmark outcome trials teach us about cardioprotection in the diabetic patient.
Cardiovascular Risk Reduction in the Setting of Diabetes and ACS
A national panel of cardiology experts, led by A. Michael Lincoff, MD, of the Cleveland Clinic, looks at glucose regulation, insulin resistance, and lipid modification as part of an overall strategy for reducing cardiovascular risk in the setting of diabetes and acute coronary syndrome.
Antithrombotic Interventions for High Risk ACS
Program Chairman Deepak L. Bhatt, MD, of Harvard Medical School, leads an expert panel in discussing novel anticoagulation strategies in the setting of PCI, looking at emerging strategies for optimizing outcomes in high risk ACS. The faculty looks at where we have been, and what the frontier looks like, from anticoagulation options to stent selection.
PPAR Agonists for Cardiovascular Risk Reduction in Diabetes and ACS
Take a close look at the evolving role of PPAR agonists for cardiovascular risk reduction in patients with type 2 diabetes and ACS with A. Michael Lincoff, MD, of the Cleveland Clinic. Dr. Lincoff looks at mechanism of action, glycemic control, insulin resistance, and dyslipedemia management and asks if PPAR agonists may be the answer.
Early Insulin Therapy and Cardiovascular Outcomes
Hertzel C. Gerstein, MD, of McMaster University, asks the question, “Does early insulin therapy improve cardiovascular outcomes in patients with dysglycemia?” Dr. Gerstein looks at recent trial data and explores the new frontiers of cardioprotection for the diabetic patient.
Cardiovascular Risk Reduction in the Setting of T2D and ACS
An international panel of experts, led by Gilles Montalescot, MD and Richard W. Nesto, discusses the new frontiers and emerging paradigms for cardiovascular risk reduction in the setting of type 2 diabetes and acute coronary syndrome.
New Frontiers and Evolving Paradigms in Cancer and Thrombosis
PROFESSOR THE LORD AJAY KAKKAR, MBBS (HONS) BSC, PHD, FRCS, of the Barts and the London School of Medicine and Dentistry in London leads a distinguished panel of cancer and thrombosis experts in reviewing critical, late-breaking, and/or challenging issues in the areas of cancer, thrombosis, VTE prophylaxis, anticoagulation; and, the role of established and investigational LMWHs and ULMWHs on patient outcomes, tumor behavior, metastases, VTE prophylaxis, and other dimensions of cancer therapy.
New Frontiers and Advances in Oral Therapy for Type 2 Diabetes
Charles Faiman, MD, of the Cleveland Clinic, chairs an expert faculty as they study the latest developments and advances in oral therapy for Type 2 diabetes, with a focus on DPP-4 inhibition and the available options, strategies and combinations for incretin-based therapy (IBT).
The Prevention of Venous Thromboembolism (VTE)
This multiple track educational program is co-sponsored by the North American Thrombosis Forum (NATF), Twine Clinical, and The Indiana University School of Medicine. The curricula are designed to demonstrate participant performance improvement and includes: 1) An Overview of Prevention of VTE as a national healthcare priority; 2) Post-Partum VTE, 3) VTE and Cancer; and 4) Heparin-Induced Thrombocytopenia.
Performance Improvement Strategies in VTE Risk Assessment and Prophylaxis (NEW!)
Co-Sponsored by the Duke University School of Medicine and Med-IQ, review evidence-based guidelines and current clinical data related to the risk assessment and prophylaxis of venous thromboembolism (VTE) among hospitalized medically ill, oncology, and/or orthopaedic surgery patients. Earn up to 20 AMA PRA Category 1 Credits for each clinical area, and use your data from the miedcailly ill and oncology initiatives to earn points for ABIM Maintenance Certification.
Atrial Fibrillation: Emerging Perspectives in Stroke Prevention for the Cardiovascular Specialist (NEW!)
Peter Libby, MD, FACC, Chief of Cardiovascular Medicine at Brigham and Women’s Hospital, chairs an expert faculty as they study the latest developments and landscape changes in atrial fibrillation, focusing on emerging strategies for stroke prevention.
Antiplatelet WRAP: Focus on Oral Antiplatlet Therapy and PPI-Drug Interactions in ACS (NEW!)
Deepak Bhatt, MD, of Harvard Medical School and the VA Boston Healthcare System, examines the evidence, guidelines, and recent studies on oral antiplatelet therapy in the front lines of cardiovascular practice, with a special emphasis on the myths and truths of drug interactions with PPIs.
Thrombosis Management
Program Chairman Samuel Z. Goldhaber, MD, of Harvard Medical School, leads an international panel of cardiologists and thrombosis experts in The iQ&A Interactive Medical Intelligence Zone for Thrombosis Management. Dr. Goldhaber and this world forum of experts address the most pressing questions on advances in anticoagulation-based therapy in the setting of atrial fibrillation, VTE and heart disease.
DVT & PE
Program Chairman Samuel Z. Goldhaber, MD, of Harvard Medical School, leads an international panel of cardiologists and thrombosis experts in The iQ&A Interactive Medical Intelligence Zone for DVT and PE. Dr. Goldhaber and this world forum of experts answer the most fequently asked questions about the role of low molecular weight heparins in the prevention of DVT and PE across the arteriovenous ris spectrum.
The New Frontiers iibrillatin Atrial Fon
There has been growing interest in identifying oral anticoagulants that can achieve safe and effective prophylaxis for stroke prevention, with minimal risk of bleeding and without the need for monitoring of clotting parameters. Samuel Z. Goldhaber, MD, of Harvard Medical School, leads an expert faculty in discussing the latest strategies for stroke prevention in the setting of atrial fibrillation, reviews the latest American College of Chest Physicians and ACC/AHA Guidelines for stroke prevention, and analyzes recent landmark clinical trials in anticoagulation.
VTECancerWRAP- A Leading Investigator, First Person Clinical Report: Focus on the Foundation Role of LMWH for VTE Management in Patients with Cancer
Thrombosis-related complications are common in patients with malignant diseases. Estimates of the prevalence of cancer among patients with venous thrombosis vary from 3% to 18%, and up to 35% of patients with cancer eventually acquire a VTE at some point in the natural history of their disease. It is now understood that the pathogenic mechanisms of thrombosis in the cancer patient involve a complex interaction among the tumor cell, the patient, and the coagulation system. Risk factors and mechanisms for thrombosis include activation of the coagulation system, platelet activation, endothelial damage, indwelling venous access devices, direct effects of chemotherapy/hormonal therapy, and host inflammatory responses. With these issues in mind, this VTECancerWRAP: A Leading Investigator, First Person Clinical Report®is one-stop CME-accredited program that provides superior quality consultation, guidance, recommendations, and clinical directives for managing cancer patients with VTE. This multimedia program, accompanied by landmark trials, guideline statements, and PowerPoint® resources, is presented by Craig M. Kessler, MD, MACP, Professor of Medicine and Pathology, Director of Division of Coagulation in the Department of Laboratory Medicine, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC.
International Cardiovascular Experts’ Roundtable: Focus on Mortality Reduction in STEMI
This innovative educational platform, The iQandA Interactive Medical Intelligence Zone for Interventional Cardiology, is a needs assessment-driven continuing medical education (CME) activity that utilizes international experts to provide evidence-based, guideline-consistent, and practice behavior-changing information focused on critical and challenging topics in clinical medicine. Frequently AskedQuestions (FAQ) reflecting the clinical needs of practitioners are answered, analyzed, and discussed by our roundtable panel of international interventional cardiology experts, who provide evidence-based and clinically relevant guidance. This edition of the iQandA Interactive Medical Intelligence Zone—Focus on Mortality Reduction in STEMI, examines the recent ESC Guidelines for STEMI and their impact on practitioners.
Cancer, Clotting, and Controversies: Critical Challenges and Landmark Advances in Thrombosis Management
Participants in this CME-certified WebCAST will: review recent trials, research, and expert analysis of issues focused on thrombosis and cancer; specify strategies for risk-directed prophylaxis against DVT in at risk patients with cancer; explain how to assess and manage special needs of cancer patients at risk for DVT, with a focus on protecting against recurrent DVT; describe how to risk stratify patients undergoing cancer surgery, and implement ACCP-mandated pharmacologic and non-pharmacologic measures aimed at DVT prophylaxis; review landmark clinical trials focusing on DVT prophylaxis in patients with cancer; explain how to appropriately use the range of pharmacologic options available for thrombosis management in patients with malignancy. The program is intended for oncologists, hematologists, coagulation experts, internists, nurse practicioners, and related disciplines.
Performance Improvement Strategies in Acute Coronary Syndromes
Treatment guidelines and hospital protocols exist for the management of patients with acute coronary syndromes (ACS), yet barriers that limit the optimal management of these patients are prevalent and achieving therapeutic goals remains a challenge. Join Christopher P. Cannon, MD, James W. Hoekstra, MD, and David M. Larson, MD, for a first-of-its-kind complimentary ACS performance improvement series, which will help you implement guideline-approved processes for your care of ACS patients, with a special focus on risk assessment, initial pharmacologic management, and door-to-needle/door-to-transfer times. Earn up to 20 AMA PRA Category 1 Credits? beginning today.
